[Palivizumab: four seasons in Russia].

In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization.

[Combined antibacterial and probiotic therapy of Helicobacter-associated diseases in children]. / Sochetannaia antibakterial'naia i probioticheskaia terapiia khelikobakterassotsiirovannykh zabolevanii u detei.

On the basis of microbiological monitoring and clinico-morphological criteria, the use of probiotics containing lacto- and bifidobacteria, simultaneously with "triple" antibacterial therapy (antibiotics of choice, metronidazole and bismuth salts), has been found to produce curative effect in the treatment of Helicobacter-associated gastroduodenal pathology in children. The influence of "triple" antibacterial therapy on the microecology of the gastrointestinal tract and the state of the immunobiological status of patients was studied. The combined scheme for correcting damaged microbiocenosis with probiotics in accordance with the concept of microecological adequacy is proposed. The scheme includes modern antibacterial therapy in combination with the probiotic preparations of lactobacteria. The prescription of bifidobacteria-containing probiotics is recommended at early stages from the beginning of etiotropic therapy. The effectiveness of the therapy may be dynamically evaluated, starting from week 5 after the end of the complex therapy, in EIA with the use of specific anti-Helicobacter antibodies.

[Detection of Campylobacter pylori in children with chronic gastritis]. / Obnaruzhenie Campylobacter pylori u detei, stradaiushchikh khronicheskim gastritom.

Examinations of the gastric mucosa biopsy specimens from 38 children suffering from chronic gastritis have revealed Campylobacter bacteria in 21 (55.3%). Studies of the cultural, morphologic, and biochemical characteristics of the isolated strains have identified them as C. pylori.

[Clinico-endoscopic characteristics and laboratory diagnosis of chronic Campylobacter gastritis in childhood]. / Kliniko-éndoskopicheskie osobennosti i laboratornaia diagnostika khronicheskogo kampilobakterioznogo gastrita v detskom vozraste.

Altogether 31 children with chronic gastritis were examined. Three diagnostic tests were employed for detecting Campylobacter pylori. The clinical signs of the disease and the endoscopic features of the gastric mucosa are described.